Here's Why Morgan Stanley Analysts Downgraded Novo Nordisk's Stock

Morgan Stanley downgraded Novo Nordisk to "underweight" from "equal weight" and reduced its price target to $47 from $59, citing concerns over stagnating U.S. demand for its GLP-1 drugs Ozempic and Wegovy, impending generic competition in ex-U.S. markets, and skepticism regarding the effectiveness of its experimental Alzheimer's treatment. This outlook, also factoring in potential Medicare Part D price cuts and competition from Eli Lilly, has contributed to a recent slide in NVO shares, extending their year-to-date decline.

Analysis

Morgan Stanley has downgraded Novo Nordisk (NVO) to "underweight" from "equal weight" and slashed its price target to $47 from $59, reflecting significant concerns over the company's growth trajectory. The downgrade is predicated on several factors, notably the observed stagnation in U.S. prescriptions for its blockbuster GLP-1 drugs, Ozempic and Wegovy. The bank's analysts forecast a decline in the U.S. GLP-1 diabetes franchise by 2026, attributing this to mounting market share and price pressures. Compounding these domestic challenges is the imminent threat of generic competition for Ozempic in ex-U.S. markets, beginning with Canada and emerging markets. Furthermore, the report casts doubt on key pipeline developments, suggesting that upcoming trial results for Novo Nordisk's GLP-1 Alzheimer's treatment are unlikely to yield statistically significant outcomes. The analysis also highlights downside risks from potential price cuts within Medicare Part D plans and questions whether Novo's experimental combination drug, CagriSemi, can effectively compete against Eli Lilly's (LLY) Zepbound. This collection of headwinds has contributed to the stock's recent decline, extending a year-to-date loss that has already erased a third of its value for U.S.-listed shares.

Key Decisions for Investors

• Investors should re-evaluate growth assumptions for Ozempic and Wegovy, as the Morgan Stanley report indicates stagnating U.S. prescriptions and projects a 2026 decline due to pricing and competitive pressures.
• Monitor the upcoming trial results for Novo Nordisk's Alzheimer's treatment, as a failure to show statistical significance, as the bank anticipates, could serve as a major negative catalyst for the stock.
• Given the stock is already down significantly year-to-date and now faces multiple headwinds, holders of NVO may consider trimming positions or implementing hedging strategies to mitigate risks from generic competition and potential Medicare price reductions.
• Closely track the competitive landscape, particularly the performance of Eli Lilly's Zepbound against Novo Nordisk's pipeline, as this will be critical in determining long-term market share in the lucrative obesity and diabetes markets.